Shanghai, China
Research view
Liver and biliary tract cancer: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- PD-1 91
- PD-L1 51
- TP53 3
- PI3K 0
- mTOR 1
- AKT 0
- STAT3 1
- VEGF 20
- FGFR 22
- GPC3 38
- CTNNB1 5
- YAP 0
- MAPK 0
- HER2 28
- NRF2 0
- HIF-1 0
- PPAR 0
- ERK 0
- AMPK 0
- STING 0
- EGFR 8
- CTLA-4 19
- MYC 0
- IDH 6
- JAK 0
- JNK 0
- PTEN 0
- GPX4 0
- KRAS 8
- BCL-2 0
- HSP90 0
- IL-6 1
- PSMA 8
- MET 1
- GLP-1 1
- BRAF 3
- EZH2 0
- NLRP3 0
- CLDN18 10
- MEK 0
- B7-H3 5
- COX-2 0
- HDAC 0
- CXCR4 0
- HMGB1 0
- METTL3 0
- SIRT1 0
- TLR4 0
- MMP-9 0
- TNF 0
- PARP 2
- PCSK9 0
- TIGIT 2
- TIM-3 1
- IL-17 0
- RAS 2
- SGLT2 0
- CD47 0
- CDK4/6 0
- IL-15 2
EU-13 is a filter, not a ranking: it only narrows the list.
Chengdu, China
Houston, United States
Hangzhou, China
Guangzhou, China
Beijing, China
Asan Medical Center · Seoul, South Korea
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Clin Cancer Res, Jan 2026Bevacizumab plus Erlotinib in Advanced Solid Cancers with Krebs Cycle Gene Mutations: A Multicenter Phase II Study (BRISK; KCSG AL22-16).
Guangzhou, China
Zhengzhou, China
Seoul, South Korea
Rozzano, Italy
Beijing, China
Shanghai, China
Clichy, France
Beijing, China
Luzhou, China
Wuhan, China
Wenzhou, China
Barcelona, Spain
Rome, Italy
National Taiwan University Hospital · Taipei, Taiwan
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Life Sci, Jan 2026Cabozantinib induces NLRP3-CASP1-GSDMD-dependent pyroptosis in hepatocellular carcinoma.
Changsha, China
Houston, United States
Harbin, China
24 of 28+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Suspended
“awaiting agreement with Sponsor”Registry text, quoted unchanged. Source
Terminated
GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
“achieve the proof of concept”Registry text, quoted unchanged. Source
Withdrawn
“The key elements of this study were incorporated into another study.”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 109
- Organoids 40
- Mendelian Randomization Analysis 38
- CRISPR-Cas Systems 34
- Gene Expression Profiling 281
- Sequence Analysis, RNA 20
- Whole Genome Sequencing 9
- Exome Sequencing 19
- Proteomics 119
- Metabolomics 73
- Mass Spectrometry 23
- Flow Cytometry 66
- Immunohistochemistry 125
- Liquid Biopsy 34
- Circulating Tumor DNA 41
- Xenograft Model Antitumor Assays 443
- Positron-Emission Tomography 35
- Magnetic Resonance Imaging 376
- Machine Learning 198
- Deep Learning 114
- Cohort Studies 184
- Genome-Wide Association Study 42
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.